Pharmacological characterization of lysophosphatidic acid-induced pain with clinically relevant neuropathic pain drugs

European Journal of Pain (United Kingdom)

Volumn 16, Issue 7, 2012, Pages 994-1004

  Ogawa, K ^a,b   Takasu, K ^a   Shinohara, S ^a   Yoneda, Y ^b   Kato, A ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; GABAPENTIN; INDOMETACIN; LIDOCAINE; LYSOPHOSPHATIDIC ACID; MEXILETINE; MILNACIPRAN; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA CONOTOXIN MVIIA; PREGABALIN; VOLTAGE GATED CALCIUM CHANNEL; 4 AMINOBUTYRIC ACID; AMINE; CACNA2D1 PROTEIN, MOUSE; CALCIUM CHANNEL; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DRUG DERIVATIVE; LYSOPHOSPHOLIPID;

ALLODYNIA; ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD DORSAL HORN; SPINAL GANGLION; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; HYPERALGESIA; METABOLISM; MOTOR ACTIVITY; NERVE CELL; NEURALGIA; SPINAL CORD;

AMINES; ANALGESICS; ANIMALS; CALCIUM CHANNELS; CYCLOHEXANECARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; GAMMA-AMINOBUTYRIC ACID; GANGLIA, SPINAL; HYPERALGESIA; INDOMETHACIN; LYSOPHOSPHOLIPIDS; MALE; MICE; MORPHINE; MOTOR ACTIVITY; NEURALGIA; NEURONS; SPINAL CORD;

EID: 84871704843     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1002/j.1532-2149.2011.00096.x     Document Type: Article

References (29)

1. Abdi S, Lee DH, Chung JM. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 1998;87:1360-6.
2. Bowersox SS, Gadbois T, Singh T, Pettus M, Wang YX, Luther RR. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J Pharmacol Exp Ther 1996;279:1243-9.
3. Bridges D, Thompson SWN, Rice ASC. Mechanisms of neuropathic pain. Br J Anaesth 2001;87:12-26.
4. Cherny NI, Thaler HT, Friedlander-Klar H, Lapin J, Foley KM, Houde R, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 1994;44:857-61.
5. Covey WC, Ignatowski TA, Knight PR, Spengler RN. Brainderived TNFalpha: involvement in neuroplastic changes implicated in the conscious perception of persistent pain. Brain Res 2000;859:113-22.
6. Fox A, Gentry C, Patel S, Kesingland A, Bevan S. Comparative activity of the anti-convulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. Pain 2003;105:355-62.
7. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med 2004;10:712-18.
8. Jett MF, McGuirk J, Waligora D, Hunter JC. The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. Pain 1997;69:161-9.
9. Kiso T, Watabiki T, Tsukamoto M, Okabe M, Kagami M, Nishimura K, et al. Pharmacological characterization and gene expression profiling of an L5/L6 spinal nerve ligation model for neuropathic pain in mice. Neuroscience 2008; 153:492-500.
10. Li CY, Zhang XL, Matthews EA, Li KW, Kurwa A, Boroujerdi A, et al. Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain 2006; 125:20-34.
11. Liu FY, Qu XX, Ding X, Cai J, Jiang H, Wan Y, et al. Decrease in the descending inhibitory 5-HT system in rats with spinal nerve ligation. Brain Res 2010;1330:45-60.
12. Ma L, Matsumoto M, Xie W, Inoue M, Ueda H. Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist. J Neurochem 2009;109:603-10.
13. Markman JD, Dworkin RH. Ion channel targets and treatment efficacy in neuropathic pain. J Pain 2006;7: S38-47.
14. Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto M, et al. Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci 2009;111:60-72.
15. Nagakura Y, Okada M, Kohara A, Kiso T, Toya T, Iwai A, et al. Allodynia and hyperalgesia in adjuvant-induced arthritic rats: time course of progression and efficacy of analgesics. J Pharmacol Exp Ther 2003;306:390-7.
16. Ohnami S, Kato A, Ono H, Tanabe M. Effect of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on C-fiber-evoked field potentials in spinal long-term potentiation and neuropathic pain. Neurosci Res 2010;68:e160.
17. Ohnami S, Tanabe M, Shinohara S, Takasu K, Kato A, Ono H. Role of voltage-dependent calcium channel subtypes in spinal long-term potentiation of C-fiber-evoked field potentials. Pain 2011;152:623-31.
18. Pandey CK, Bose N, Garg G, Singh N, Baronia A, Agarwal A, et al. Gabapentin for the treatment of pain in Guillain- Barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg 2002;95:1719-23.
19. Rashid MH, Inoue M, Toda K, Ueda H. Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain. J Pharmacol Exp Ther 2004;309:380-7.
20. Sakaue A, Honda M, Tanabe M, Ono H. Antinociceptive effects of sodium channel-blocking agents on acute pain in mice. J Pharmacol Sci 2004;95:181-8.
21. Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002;96:119-27.
22. Solaro C, Lunardi GL, Capello E, Inglese M, Messmer Uccelli M, Uccelli A, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998;5:609-11.
23. Suzuki T, Ueta K, Tamagaki S, Mashimo T. Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. Anesth Analg 2008;106:1309-15.
24. Takasu K, Ogawa K, Shinohara S, Kato A. Injury-specific functional alteration of N-type voltage gated calcium channels on C-afferent terminals in substantia gelatinosa of spinal cord. Neurosci Res 2009;65:178.
25. Takeuchi Y, Takasu K, Ono H, Pregabalin TM. S-(+)-3- isobutylgaba, activates the descending noradrenergic system to alleviate neuropathic pain in the mouse partial sciatic nerve ligation model. Neuropharmacology 2007; 53:842-53.
26. Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin-calcium channel alpha2-delta [Cavalpha2- delta] ligands. Pain 2009;142:13-16.
27. Ueda H. Peripheral mechanisms of neuropathic pain - involvement of lysophosphatidic acid receptor-mediated demyelination. Mol Pain 2008;4:11-23.
28. Wang YX, Pettus M, Gao D, Phillips C, Scott Bowersox S. Effects of intrathecal administration of ziconotide, a selective neuronal N-type calcium channel blocker, on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain. Pain 2000;84:151-8.
29. Zhang WS, Xu H, Xu B, Sun S, Deng XM, Zhang YQ. Antihyperalgesic effect of systemic dexmedetomidine and gabapentin in a rat model of monoarthritis. Brain Res 2009;1264:57-66.